top of page
We are proud to launch
our first proprietary product
Phoulkon, a food for Special Medical Purposes specifically formulated for oncological patients undergoing radiotherapy and suffering from RIOM (Radiation Induced Oral Mucositis).
News
In October 2022, Phoulkon underwent in vitro test, with very interesting outcomes, and it’s now undergoing an observational clinical trial involving 8 hospitals in Italy with an ongoing recruitment of 60 patients.
After this phase it’s planned a double-blind, crossover, randomized clinical trial enrolling 50- 60 patients.
Our patented complex will be further involved in the development of further FSMP (food for special medical purposes) for other clinical applications, food supplements, and medical devices.
bottom of page